State of the art lipid based delivery solutions

State-of-the-art lipid-based delivery solutions to enhance the potential of mRNA immuno-cell therapy

On-Demand Webinar in Japanese

Generally, gene transfer into blood cells has been done by lentivirus in the well-known CAR-T production or by electroporation in academia. Our series of cationic lipid-based mRNA delivery reagents containing IM21.7c as a raw material have achieved various types of transfection into blood cells, overturning these conventional methods. In this webinar, we will share the results of these studies and expect that it will be helpful for the development of transgenic T cells in the future.

What You Will Learn:

Explore the key compound LipidBrick IM21.7c enables smooth development from basic research to industrialization.
How to overcome the high cost of viral transfection and low productivity of electroporation.
About IM21.7c, which has more pronounced liver avoidance characteristics than conventional ionized or cationic lipids.

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

Complete Form to Register

Takio Nihei

Commercial Development Manager

Takio Nihei completed his master’s degree in food science research on taste sensor mechanism. After graduating, he has started his carrier in publishing and advertising at the life-tech publisher and distributor, and also has shifted to contract business development from the point of smooth implementation between life-tech ventures and customers. Since end of 2020, he has been engaged in sales activities targeting early stage of R&D researchers in translational research in the position of former Polyplus-transfection, and from 2024, he has expanded his scope as a member of the Advanced Therapy Solution at Sartorius, which now covers Polyplus modalities.